Efficacy and safety of platelet glycoprotein receptor blockade in aged and comorbid mice with acute experimental stroke

Stroke

Volumn 46, Issue 12, 2015, Pages 3502-3506

  Kraft, Peter ^a   Schuhmann, Michael K ^a   Fluri, Felix ^a   Lorenz, Kristina ^b   Zernecke, Alma ^a   Stoll, Guido ^a   Nieswandt, Bernhard ^c   Kleinschnitz, Christoph ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

^c UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

middle cerebral artery occlusion; platelet aggregation inhibitors; streptozotocin; stroke; translation

Indexed keywords

ANTICOAGULANT AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; GLYCOPROTEIN IB ANTIGEN BINDING FRAGMENT ANTIBODY; GLYCOPROTEIN IIB IIIA ANTIGEN BINDING FRAGMENT ANTIBODY; GLYCOPROTEIN VI MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG; FIBRINOGEN RECEPTOR; IMMUNOGLOBULIN F(AB) FRAGMENT;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ARTICLE; ATHEROSCLEROSIS; BLEEDING DISORDER; BLOOD CLOTTING; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CLINICAL ASSESSMENT; COMORBIDITY; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; ENZYME INHIBITION; EXPERIMENTAL STROKE; HYPERTENSION; MALE; MIDDLE CEREBRAL ARTERY OCCLUSION; MOUSE; NERVE DEGENERATION; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; AGING; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG EFFECTS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; STROKE; TRANSGENIC MOUSE; TREATMENT OUTCOME;

AGING; ANIMALS; DISEASE MODELS, ANIMAL; IMMUNOGLOBULIN FAB FRAGMENTS; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; STROKE; TREATMENT OUTCOME;

EID: 84948092825     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.115.011114     Document Type: Article

References (24)

1. Mukherjee D, Patil CG., Epidemiology and the global burden of stroke. World Neurosurg 2011 76 6 suppl S85 S90. doi: 10.1016/j.wneu.2011.07.023.
2. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; and Council on Peripheral Vascular Disease Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014 45 2160 2236. doi: 10.1161/STR.0000000000000024.
3. Kleinschnitz C, Pozgajova M, Pham M, Bendszus M, Nieswandt B, Stoll G., Targeting platelets in acute experimental stroke: impact of glycoprotein Ib, VI, and IIb/IIIa blockade on infarct size, functional outcome, and intracranial bleeding. Circulation 2007 115 2323 2330. doi: 10.1161/CIRCULATIONAHA.107.691279.
4. Kraft P, De Meyer SF, Kleinschnitz C., Next-generation antithrombotics in ischemic stroke: preclinical perspective on 'bleeding-free antithrombosis'. J Cereb Blood Flow Metab 2012 32 1831 1840. doi: 10.1038/jcbfm.2012.108.
5. O'Collins VE, Macleod MR, Donnan GA, Horky LL, van der Worp BH, Howells DW., 1,026 experimental treatments in acute stroke. Ann Neurol 2006 59 467 477. doi: 10.1002/ana.20741.
6. Albers GW, Goldstein LB, Hess DC, Wechsler LR, Furie KL, Gorelick PB, STAIR VII Consortium Stroke Treatment Academic Industry Roundtable (STAIR) recommendations for maximizing the use of intravenous thrombolytics and expanding treatment options with intra-Arterial and neuroprotective therapies. Stroke 2011 42 2645 2650. doi: 10.1161/STROKEAHA.111.618850.
7. Animal Research: Reporting of In VIVO Experiments (ARRIVE). https://www.nc3rs.org.uk/arrive-guidelines
8. Buono C, Pang H, Uchida Y, Libby P, Sharpe AH, Lichtman AH., B7-1/B7-2 costimulation regulates plaque antigen-specific T-cell responses and atherogenesis in low-density lipoprotein receptor-deficient mice. Circulation 2004 109 2009 2015. doi: 10.1161/01.CIR.0000127121.16815.F1.
9. Caron KM, James LR, Kim HS, Morham SG, Sequeira Lopez ML, Gomez RA, A genetically clamped renin transgene for the induction of hypertension. Proc Natl Acad Sci U S A 2002 99 8248 8252. doi: 10.1073/pnas.112222199.
10. Dirnagl U., Bench to bedside: the quest for quality in experimental stroke research. J Cereb Blood Flow Metab 2006 26 1465 1478. doi: 10.1038/sj.jcbfm.9600298.
11. Kraft P, Göb E, Schuhmann MK, Göbel K, Deppermann C, Thielmann I, FTY720 ameliorates acute ischemic stroke in mice by reducing thrombo-inflammation but not by direct neuroprotection. Stroke 2013 44 3202 3210. doi: 10.1161/STROKEAHA.113.002880.
12. Nieswandt B, Schulte V, Bergmeier W, Mokhtari-Nejad R, Rackebrandt K, Cazenave JP, Long-Derm antithrombotic protection by in vivo depletion of platelet glycoprotein VI in mice. J Exp Med 2001 193 459 469
13. Langhauser F, Göb E, Kraft P, Geis C, Schmitt J, Brede M, Kininogen deficiency protects from ischemic neurodegeneration in mice by reducing thrombosis, blood-brain barrier damage, and inflammation. Blood 2012 120 4082 4092. doi: 10.1182/blood-2012-06-440057.
14. Kraft P, Benz PM, Austinat M, Brede ME, Schuh K, Walter U, Deficiency of vasodilator-stimulated phosphoprotein (VASP) increases blood-brain-barrier damage and edema formation after ischemic stroke in mice. PLoS One 2010 5 e15106. doi: 10.1371/journal.pone.0015106.
15. Richard Green A, Odergren T, Ashwood T., Animal models of stroke: do they have value for discovering neuroprotective agents? Trends Pharmacol Sci 2003 24 402 408. doi: 10.1016/S0165-6147(03)00192-5.
16. Kraft P, Drechsler C, Gunreben I, Heuschmann PU, Kleinschnitz C., Regulation of blood coagulation factors XI and XII in patients with acute and chronic cerebrovascular disease: a case-control study. Cerebrovasc Dis 2014 38 337 343. doi: 10.1159/000368434.
17. Nieswandt B, Aktas B, Moers A, Sachs UJ., Platelets in atherothrombosis: lessons from mouse models. J Thromb Haemost 2005 3 1725 1736. doi: 10.1111/j.1538-7836.2005.01488.x.
18. Nieswandt B, Kleinschnitz C, Stoll G., Ischaemic stroke: a thrombo-inflammatory disease? J Physiol 2011 589 Pt 17 4115 4123. doi: 10.1113/jphysiol.2011.212886.
19. Adams HP Jr, Effron MB, Torner J, Dávalos A, Frayne J, Teal P, AbESTT-II Investigators Emergency administration of abciximab for treatment of patients with acute ischemic stroke: results of an international phase III trial: Abciximab in Emergency Treatment of Stroke Trial (AbESTT-II). Stroke 2008 39 87 99. doi: 10.1161/STROKEAHA.106.476648.
20. Bhatt DL, Topol EJ., Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov 2003 2 15 28. doi: 10.1038/nrd985.
21. Rozalski M, Kassassir H, Siewiera K, Klepacka A, Sychowski R, Watala C., Platelet activation patterns are different in mouse models of diabetes and chronic inhibition of nitric oxide synthesis. Thromb Res 2014 133 1097 1104. doi: 10.1016/j.thromres.2014.03.041.
22. Sutherland GR, Dix GA, Auer RN., Effect of age in rodent models of focal and forebrain ischemia. Stroke 1996 27 1663 1667; discussion 1668
23. Shapira S, Sapir M, Wengier A, Grauer E, Kadar T., Aging has a complex effect on a rat model of ischemic stroke. Brain Res 2002 925 148 158
24. Duverger D, MacKenzie ET., The quantification of cerebral infarction following focal ischemia in the rat: influence of strain, arterial pressure, blood glucose concentration, and age. J Cereb Blood Flow Metab 1988 8 449 461. doi: 10.1038/jcbfm.1988.86.